Eat, Move, Live Program for the Reduction of Cancer and Chronic Disease Risk in Underserved Communities

Reducing Cancer and Chronic Disease Risk in Underserved Communities: Eat, Move, Live Program

This clinical trial tests the Eat, Move, Live (EML) Program in reducing the risk of chronic diseases among underserved communities by improving healthy lifestyle practices, increasing physical activity and encouraging healthy eating behaviors. EML is a series of free culturally and linguistically appropriate nutrition and physical activity sessions. The interactive education segment of the EML Program is culturally responsive, and based on the community EML program, and topics will include: nutrition guidelines, reading food labels, recipe modification and healthy food preparation, eating healthy on a budget, chronic diseases information and prevention strategies. The EML program may help reduce the risk of cancer and chronic diseases by encouraging more physical activity and healthy eating behaviors.

Study Overview

• Status: Active, not recruiting
• Conditions: Diabetes Mellitus; Obesity-Related Malignant Neoplasm
• Intervention / Treatment: Other: Questionnaire Administration; Behavioral: Behavioral Intervention

Detailed Description

PRIMARY OBJECTIVES:

I. To evaluate program by assessing in combination with standard of care metformin: Changes in participants' knowledge, attitudes, and behavior.

II. To evaluate program by assessing in combination with standard of care metformin: Changes in body measurements.

III. To evaluate program by assessing in combination with standard of care metformin: Changes in biomarkers.

OUTLINE:

Participants attend EML program sessions weekly for 12 weeks including an educational session chronic disease risk reduction via nutrition and physical activity, a physical activity session, and a cooking/taste test demonstration.

• Study Type: Interventional
• Enrollment (Actual): 347
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Duarte, California, United States, 91010
      • City of Hope Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Agrees to group consent at week 1
• Age over 18
• Able to speak and understand English and/or Spanish

Exclusion Criteria:

• Don't agree to group consent at week 1
• Age younger than 18
• Not able to speak and understand English and/or Spanish
• Can't participate in physical activity

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Supportive care (EML program); Participants attend EML program sessions weekly for 12 weeks including an educational session chronic disease risk reduction via nutrition and physical activity, a physical activity session, and a cooking/taste test demonstration.	Other: Questionnaire Administration; Ancillary studies; Behavioral: Behavioral Intervention; Attend EML program sessions; Other Names: Behavior Conditioning Therapy; Behavior Modification; Behavior or Life Style Modifications; Behavior Therapy; Behavioral Interventions; Behavioral Modification; Behavioral Therapy; Behavioral Treatment; Behavioral Treatments

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in attitudes and beliefs as measured by questionnaires from baseline to week 12	Attitudes and beliefs regarding causes of diabetes asked in questionnaire, measured by endorsing one of the Likert-type scale values ranging from 1 (Agree) to 7 (Disagree).	Baseline and week 12
Changes in behavior as measured by questionnaires from baseline to week 12	Behaviors related to food consumption asked in questionnaires, measured by endorsing one of "None", "1", "2-3", "4-6", "7 or more".	Baseline and week 12
Changes in height from baseline to week 12	Height measured in meters	Baseline to 12 weeks
Changes in weight from baseline to week 12	Weight measured in Kilograms	Baseline to 12 weeks
Changes in waist circumference from baseline to week 12	Hip circumference measured in centimeters	Baseline to 12 weeks
Changes in chest circumference from baseline to week 12	Chest circumference measured in centimeters	Baseline to 12 weeks
Changes in right upper arm circumference from baseline to week 12	Right upper arm circumference measured in centimeters	Baseline to 12 weeks
Changes in left upper arm circumference from baseline to week 12	Left upper arm circumference measured in centimeters	Baseline to 12 weeks
Changes in right upper thigh circumference from baseline to week 12	Right upper thigh circumference measured in centimeters	Baseline to 12 weeks
Changes in left upper thigh circumference from baseline to week 12	Left upper thigh circumference measured in centimeters	Baseline to 12 weeks
Changes in body fat percentage from baseline to week 12	Body fat percentage measured in percent using a handheld BMI machine that calculates body fat percentage.	Baseline to 12 weeks
Changes in systolic blood pressure from baseline to week 12	Systolic blood pressure measured in mmHG	Baseline to 12 weeks
Changes in diastolic blood pressure from baseline to week 12	Diastolic blood pressure measured in mmHG	Baseline to 12 weeks
Changes in hip circumference from baseline to week 12	Hip circumference measured in centimeters	Baseline to 12 weeks
Changes in biomarkers	Will be collected at baseline and follow up based on glycosylated hemoglobin (A1C) measuring guidelines.	Baseline to 12 weeks

Collaborators and Investigators

• Sponsor: City of Hope Medical Center
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Victoria L Seewaldt, City of Hope Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): March 20, 2018
• Primary Completion (Estimated): October 12, 2026
• Study Completion (Estimated): October 12, 2026

Study Registration Dates

• First Submitted: March 24, 2022
• First Submitted That Met QC Criteria: June 8, 2022
• First Posted (Actual): June 10, 2022

Study Record Updates

• Last Update Posted (Actual): December 5, 2025
• Last Update Submitted That Met QC Criteria: December 3, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Glucose Metabolism Disorders; Nutritional and Metabolic Diseases; Diabetes Mellitus; Psychotherapy; Behavioral Disciplines and Activities; Behavior Therapy
• Other Study ID Numbers: 17410 (Other Identifier: City of Hope Comprehensive Cancer Center); P30CA033572 (U.S. NIH Grant/Contract); NCI-2022-00180 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No